1.74
-0.14(-7.45%)
Currency In USD
| Previous Close | 1.88 |
| Open | 1.84 |
| Day High | 1.91 |
| Day Low | 1.74 |
| 52-Week High | 2.37 |
| 52-Week Low | 0.65 |
| Volume | 494,244 |
| Average Volume | 421,246 |
| Market Cap | 119.95M |
| PE | -0.94 |
| EPS | -1.86 |
| Moving Average 50 Days | 1.83 |
| Moving Average 200 Days | 1.23 |
| Change | -0.14 |
If you invested $1000 in Opus Genetics, Inc. (IRD) since IPO date, it would be worth $21,750 as of November 18, 2025 at a share price of $1.74. Whereas If you bought $1000 worth of Opus Genetics, Inc. (IRD) shares 1 year ago, it would be worth $1,348.84 as of November 18, 2025 at a share price of $1.74.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease
GlobeNewswire Inc.
Nov 13, 2025 12:00 PM GMT
Emerging gene therapy administered through a one-time subretinal injection marks a major milestone for the inherited retinal disease community Initial data expected in Q1 2026 RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Opus Gen
Opus Genetics Announces $23 Million Registered Direct Offering
GlobeNewswire Inc.
Nov 06, 2025 12:00 PM GMT
- Financing led by Perceptive Advisors and Balyasny Asset Management - - Proceeds targeted to fund rapid development of ophthalmic gene therapy clinical programs - RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc.
Opus Genetics Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease
GlobeNewswire Inc.
Nov 06, 2025 12:00 PM GMT
Outcome of Regenerative Medicine Advanced Therapy (RMAT) meeting provides the potential for an accelerated regulatory pathway to approval of OPGx-LCA5First participant enrolled in run-in period for planned adaptive Phase 3 trialCompany intends to app